Overview
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.
We are aware that a number of services are keen to understand national timelines for commissioning decisions regarding further rollout of CYP2C19 testing via NHS Genomic Medicine Service laboratories, prior to the use of clopidogrel following stroke in line with NICE healthtech guidance 724.
NHS England confirmed that information from the pilot has informed the development of implementation guidance to inform a future national commissioning approach. However, it has not been possible to identify the necessary recurrent headroom in revenue budgets to support the routine commissioning of this testing for the indicated population at this point in time. This position is being kept under active review and takes into account the need to maintain all existing services for patients that currently receive genomic testing delivered by the NHS Genomic Medicine Service. An implementation guide has been produced by the NHS Pharmacogenomics and Medicines Optimisation Network of Excellence.
Last reviewed: 31 July 2024
Diagnostics guidance 59 has been migrated to HealthTech guidance 724.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.